ICON Medical Imaging Selects AG Mednet
OEM agreement brings full suite of AG Mednet quality assurance, submission compliance and image transfer technology to leading provider of medical imaging research services
BOSTON, June 26, 2012 /PRNewswire/ --
More than half of all image-related clinical trial query stoppages result from preventable human errors, according to industry research. On average, preventable mistakes delay a clinical trial for up to seven weeks, costing trial sponsors more than $8 million a day. AG Mednet's automated quality assurance technology reduces submission error rates at the source and brings preventable delays to zero.
ICON was the first imaging core laboratory to integrate with the AG Mednet solution, and this OEM agreement represents the culmination of a collaboration that recognizes AG Mednet as the industry leading solution for the collection of clinical trial medical images from study centers. "The reductions in queries, data quality issues, and time-to-receipt are fundamental components in ICON's vision of a fully automated end-to-end, zero-delay clinical trial management environment for our sites and sponsors," said Andrew Kraus, Executive Vice President of ICON Global Data Technologies.
AG Mednet's technology and services will integrate with ICON's MIRA™ and CTMS to provide sponsors and sites with the most advanced image data collection and delivery system in the market. AG Mednet supports all organizations in the clinical trial ecosystem: core labs, clinical research organizations, pharmaceutical companies and principal investigators.
"This OEM agreement is the culmination of years of collaboration and hard work between our companies," said Abraham Gutman, President and CEO of AG Mednet. "ICON Medical Imaging has a far-reaching quality management vision that will reduce the burden on sites, increase trial efficiency and strengthen protocol compliance across all therapeutic areas."
For more information about AG Mednet's
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025